News

The company expects to launch Altrazeal in Austria in October 2012. Melmed Holdings chairman Helmut Kerschbaumer said the clinical and economic advantages that have been demonstrated are significant

Pursuant to the agreement, the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) will focus on identifying drug candidates from a program already receiving support from The Michael J.

The company has announced immediate shipment of the product. The generic version of Pfizer’s Antivert is indicated for the management of nausea and vomiting, and dizziness associated with

Quintiles Infosario solution integrates data, systems, processes and Quintiles’ therapeutic knowledge to have better-informed decisions from clinical trial planning and design, to trial execution services, through post-market outcome

The positive results from REV technology have induced the pharma company to actively participate in the testing program, which aims to refine the processes and seek FDA approval

The implementation includes Revitas CARS, CARS BI, Medicaid Rebates and Government Pricing solutions. Glenmark executive vice president Paul Dutra said the Flex platform is an end-to-end automated solution

Omkar Speciality Chemicals chairman and managing director Pravin Herlekar was quoted by business-standard as saying that though some high-end molecules are ready for commercialization, the company is facing

The partnership will focus on developing self-injectable treprostinil molecule, the active ingredient in Remodulin (treprostinil) injection, for pulmonary arterial hypertension (PAH). The TransCon technology platform is expected enhance

Under the collaboration, GNS will use its supercomputer-driven Reverse Engineering and Forward Simulation (REFS) platform, while Covance will utilize its data assets derived from its extensive clinical and